Live attenuated vaccine

The first clinically approved dengue vaccine?

Katja Fink, Pei-Yong Shi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. There are 390 million human infections each year, with 96 million infections exhibiting disease symptoms. Currently, there is no clinically approved vaccine and antiviral for DENV. The four serotypes of DENV (DENV-1, -2, -3 and -4) have 25-40% variation at the amino acid level. Such variation has posed challenges for the development of a tetravalent vaccine and therapeutics.

Original languageEnglish (US)
Pages (from-to)185-188
Number of pages4
JournalExpert Review of Vaccines
Volume13
Issue number2
DOIs
StatePublished - Feb 2014
Externally publishedYes

Fingerprint

Dengue Vaccines
Attenuated Vaccines
Dengue Virus
Vaccines
Infection
Culicidae
Antiviral Agents
Amino Acids

Keywords

  • antibodies
  • dengue
  • live-attenuated
  • T cells
  • vaccine

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Live attenuated vaccine : The first clinically approved dengue vaccine? / Fink, Katja; Shi, Pei-Yong.

In: Expert Review of Vaccines, Vol. 13, No. 2, 02.2014, p. 185-188.

Research output: Contribution to journalArticle

@article{a7b2d65ebc3b42c2ab925ac135f21a5a,
title = "Live attenuated vaccine: The first clinically approved dengue vaccine?",
abstract = "Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. There are 390 million human infections each year, with 96 million infections exhibiting disease symptoms. Currently, there is no clinically approved vaccine and antiviral for DENV. The four serotypes of DENV (DENV-1, -2, -3 and -4) have 25-40{\%} variation at the amino acid level. Such variation has posed challenges for the development of a tetravalent vaccine and therapeutics.",
keywords = "antibodies, dengue, live-attenuated, T cells, vaccine",
author = "Katja Fink and Pei-Yong Shi",
year = "2014",
month = "2",
doi = "10.1586/14760584.2014.870888",
language = "English (US)",
volume = "13",
pages = "185--188",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Live attenuated vaccine

T2 - The first clinically approved dengue vaccine?

AU - Fink, Katja

AU - Shi, Pei-Yong

PY - 2014/2

Y1 - 2014/2

N2 - Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. There are 390 million human infections each year, with 96 million infections exhibiting disease symptoms. Currently, there is no clinically approved vaccine and antiviral for DENV. The four serotypes of DENV (DENV-1, -2, -3 and -4) have 25-40% variation at the amino acid level. Such variation has posed challenges for the development of a tetravalent vaccine and therapeutics.

AB - Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. There are 390 million human infections each year, with 96 million infections exhibiting disease symptoms. Currently, there is no clinically approved vaccine and antiviral for DENV. The four serotypes of DENV (DENV-1, -2, -3 and -4) have 25-40% variation at the amino acid level. Such variation has posed challenges for the development of a tetravalent vaccine and therapeutics.

KW - antibodies

KW - dengue

KW - live-attenuated

KW - T cells

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=84893051489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893051489&partnerID=8YFLogxK

U2 - 10.1586/14760584.2014.870888

DO - 10.1586/14760584.2014.870888

M3 - Article

VL - 13

SP - 185

EP - 188

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 2

ER -